174 related articles for article (PubMed ID: 35895075)
21. Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001.
Vrooman LM; Blonquist TM; Stevenson KE; Supko JG; Hunt SK; Cronholm SM; Koch V; Kay-Green S; Athale UH; Clavell LA; Cole PD; Harris MH; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Place AE; Schorin MA; Welch JJG; Neuberg DS; Sallan SE; Silverman LB
J Clin Oncol; 2021 Nov; 39(31):3496-3505. PubMed ID: 34228505
[TBL] [Abstract][Full Text] [Related]
22. Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea.
Lee JH; Lee J; Yhim HY; Oh D; Bang SM
J Thromb Haemost; 2017 Apr; 15(4):655-661. PubMed ID: 28150907
[TBL] [Abstract][Full Text] [Related]
23. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
[TBL] [Abstract][Full Text] [Related]
24. Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma.
August KJ; Farooki S; Fulbright JM; August A; Portnoy JM; Pommert L; Burke MJ; Guest EM
Pediatr Blood Cancer; 2020 Jan; 67(1):e28021. PubMed ID: 31571395
[TBL] [Abstract][Full Text] [Related]
25. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
[TBL] [Abstract][Full Text] [Related]
26. Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.
Kashanian SM; Holtzman NG; Patzke CL; Cornu J; Duffy A; Koka M; Niyongere S; Duong VH; Baer MR; Apata J; Kamangar F; Emadi A
Cancer Chemother Pharmacol; 2021 Jun; 87(6):817-826. PubMed ID: 33677674
[TBL] [Abstract][Full Text] [Related]
27. Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group.
Brigitha LJ; Fiocco M; Pieters R; Albertsen BK; Escherich G; Lopez-Lopez E; Mondelaers V; Vora A; Vrooman L; Schmiegelow K; van der Sluis IM;
Eur J Cancer; 2022 Feb; 162():65-75. PubMed ID: 34954438
[TBL] [Abstract][Full Text] [Related]
28. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
[TBL] [Abstract][Full Text] [Related]
29. Levocarnitine for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia.
Schulte R; Hinson A; Huynh V; Breese EH; Pierro J; Rotz S; Mixon BA; McNeer JL; Burke MJ; Orgel E
Cancer Med; 2021 Nov; 10(21):7551-7560. PubMed ID: 34528411
[TBL] [Abstract][Full Text] [Related]
30. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
Heo YA; Syed YY; Keam SJ
Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
[TBL] [Abstract][Full Text] [Related]
31. SOHO State of the Art Updates and Next Questions: Management of Asparaginase Toxicity in Adolescents and Young Adults with Acute Lymphoblastic Leukemia.
Schmiegelow K; Rank CU; Stock W; Dworkin E; van der Sluis I
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):725-733. PubMed ID: 34511319
[TBL] [Abstract][Full Text] [Related]
32. Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.
Burke PW; Aldoss I; Lunning MA; Devlin SM; Tallman MS; Pullarkat V; Mohrbacher AM; Douer D
Leuk Res; 2018 Mar; 66():49-56. PubMed ID: 29407583
[TBL] [Abstract][Full Text] [Related]
33. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R
Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991
[TBL] [Abstract][Full Text] [Related]
34. Relapse risk following truncation of pegylated asparaginase in childhood acute lymphoblastic leukemia.
Gottschalk Højfeldt S; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Marquart HV; Vaitkeviciene G; Lepik K; Heyman M; Schmiegelow K; Albertsen BK
Blood; 2021 Apr; 137(17):2373-2382. PubMed ID: 33150360
[TBL] [Abstract][Full Text] [Related]
35. Predicting success of desensitization after pegaspargase allergy.
Swanson HD; Panetta JC; Barker PJ; Liu Y; Inaba H; Relling MV; Pui CH; Karol SE
Blood; 2020 Jan; 135(1):71-75. PubMed ID: 31750901
[No Abstract] [Full Text] [Related]
36. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
[TBL] [Abstract][Full Text] [Related]
38. Toxicity study of pegaspargase.
Ettinger LJ; Lerner ED; Manglani MV
Indian Pediatr; 2000 Jun; 37(6):631-6. PubMed ID: 10869143
[No Abstract] [Full Text] [Related]
39. Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
Albertsen BK; Harila-Saari A; Jahnukainen K; Lähteenmäki P; Riikonen P; Möttönen M; Lausen B
Leuk Lymphoma; 2019 Jun; 60(6):1469-1475. PubMed ID: 30632847
[TBL] [Abstract][Full Text] [Related]
40. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Christ TN; Stock W; Knoebel RW
J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]